USC linebacker Porter Gustin might have seen his draft stock take a hit after a most recent report. Ian Rapoport reported that Gustin failed a PED (performance enhancing drugs) test in Indianapolis at the NFL Scouting Combine.
Rapoport states that Gustin is prescribed Adderall for therapeutic use. It is a real possibility that Adderall was the drug found in the test. The NFL’s stance on Adderall is particularly interesting.
During the season, Adderall is considered a PED. However, in the offseason, it is regarded as a recreational drug.
#USC LB Porter Gustin, a projected late-round pick, failed a PED drug test at the Combine, sources say. Per Gustin’s agent, he was granted temporary Therapeutic Use Exemption for Adderall following the Combine that takes him through September. At that point, he’ll reapply.
— Ian Rapoport (@RapSheet) April 24, 2019
Since it is currently the NFL’s offseason Gustin might have failed the test, not on account of Adderall, but another performance-enhancing drug. Per Pro Football Talk, “It’s possible, if not likely, that Gustin tested positive for a PED, and that his Adderall exemption is unrelated to the PED for which he tested positive. This is something that anyone interested in drafting or signing Gustin (if he’s undrafted) will have to figure out.”
Either way, this does not bode well for Gustin. He is projected to be a late round pick and might even go undrafted with this most recent report. The NFL draft is only one day away and Rapoport delivered life-changing news at seemingly the worst time possible for Gustin.
The 2019 NFL Draft will take place between April 25 and April 27 in Nashville, Tennessee. Nashville earned the honor of hosting the 84th annual player selection over cities Denver, Kansas City, Las Vegas, and Cleveland/Canton.